The prophylactic potency of topically applied human leukocyte interferon and human fibroblast interferon was compared in a monkey model with herpes simplex virus type 1-induced keratitis. Both interferons effectively prevented keratitis at 1.9 x 106 U of activity per ml but were ineffective at 1.9 x 103 U/ml.
Slight differences between human leukocyte interferon and human fibroblast interferon observed at the level of 1.9 x 105 U/ml were not statistically significant.
The antiviral effect of topically applied interferon has been demonstrated in herpes simplex virus type 1 (HSV-1)-induced epithelial keratitis in non-human primates and man (5, 6, (8) (9) (10) . All controlled studies thus far have utilized human leukocyte interferon (HLI). In addition to HLI, increasing quantities of human fibroblast interferon (HFI) are becoming available. As differences in the biological properties and the molecular characteristics have been reported between HLI and HFI (2, 3, 7), a comparison of their potency in a well-established monkey model was desirable before further clinical studies.
HSV-1 keratitis was induced in African green monkeys in the same way as described previously (6) , except for the dose of infecting virus, which was 2 x 107 mean tissue culture infective doses per inoculum (0.1 ml), guaranteeing a 100% incidence of keratitis. Ophthalmological examinations, virus isolations, assays of interferon activity, and interferon treatment were performed as described previously (6) . HLI was induced in primary human leukocytes by live Sendai virus (1). Its specific activity was 106 U/mg of protein. HFI was produced in diploid human foreskin fibroblasts (FS-4, provided by J. Vilcek, New York) by superinduction, using polyinosinic acid:polycytidylic acid as an inducer (4) . The specific activity of HFI was 3.3 x 105 U/mg of protein.
Both interferons were adjusted to the activity of 1.9 x 106 U/ml by the addition of phosphatebuffered saline containing 0.3% human albumin and were titrated by serial 10-fold dilutions in the same medium to 1.9 x 103 U/ml. The right eyes of eight groups of four monkeys each were treated with either HLI or HFI in 10-fold dilutions at three times: 13 h before, immediately before, and 24 h after infection. Diluent was used in the 32 left eyes for mock treatment. The volume of each dose was 0.05 ml.
Before the instillation of interferon or diluent, each eye was anesthetized by 1 drop of proxymetacaine (10) .
All of 32 HSV-1-infected, mock-treated eyes developed herpetic keratitis and shed infectious HSV-1 3 days postinoculation. Treatment with either HLI or HFI resulted in complete protection from keratitis when preparations at 1.9 x 106 U/ml were applied (Table 1) . However, at 1.9 x 103 U/ml both preparations were absolutely ineffective (Tables 1 and 2 ). HLI and HFI were marginally effective at 1.9 x< 104 U/ml.
The difference between the HLI and the HFI groups (III and VII) was based only on a biomicroscopically diagnosed, small herpetic lesion in monkey VII/4, the specificity of which was not virologically confirmed. All other results of virus isolation were in accord with the observed herpetic corneal lesions.
The 50% end point of the prophylactic effect for HFI was at 1.9 x 105 U/ml. At this level of activity HLI seemed to be slightly more effective than HFI. HLI protected more monkeys from keratitis than HFI (Table 1) , and the clinical score of the only diseased monkey in this HLI group (II/2) was lower than the mean score in the corresponding HFI group. However, these differences are not statistically significant.
Another slight difference, which cannot be precisely scored, consisted of a reversible toxic effect on the comneal epithelium, which had been observed previously (6) with HLI in mon- (3 tests) activities, and when restricted to those disease states (10) that permit a beneficial action of the interferon mechanism.
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